SCHEMBL8086282

SCHEMBL8086282

C=C(Nc1cccc(OC)c1)c1ccc(NCCC)c(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
MTNR1B P49286 3/20 0.42
PKM P14618 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
EPHX2 P34913 2/20 0.40
MTNR1A P48039 2/20 0.40
TAAR1 Q96RJ0 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8086764 0.92 RAB9A (0.45) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL4250840 0.88 RAB9A (0.56) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL4249452 0.82 MAPT (0.56) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL4254188 0.79 RAB9A (0.56) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL4247305 0.79 RAB9A (0.58) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL8086791 0.74 NPC1 (0.51) MAPTRAB9ANPC1MTNR1BPKM
SCHEMBL4251690 0.73 RAB9A (0.56) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL8086177 0.73 RAF1 (0.53) NPC1ALDH1A1TAAR1
SCHEMBL4247072 0.73 RXFP1 (0.62) MAPTRAB9ANPC1PKMALDH1A1
SCHEMBL2090211 0.72 MTNR1B (0.62) MAPTRAB9ANPC1MTNR1BPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed